Skip to main content

Table 1 Patient characteristics

From: Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations

Median (range)

All patients

gBRCA1

gBRCA2

p value (gBRCA1 vs. gBRCA2)

TP53

wild type

(N = 15)

TP53 mutant

(N = 12)

p value

TP53

wild type

(N = 19)

TP53 mutant

(N = 9)

p value

Sex

 Female

54 (98.2%)

15 (100.0%)

12 (100.0%)

1.000

18 (94.7%)

9 (100.0%)

1.000

1.000

 Male

1 (1.8%)

   

1 (5.3%)

0 (0.0%)

  

Age at diagnosis

42.0 (27–71)

45.0 (29–67)

39.5 (28–55)

0.406

39.0 (27–57)

45.0 (27–71)

0.941

0.980

Family history

34 (61.8%)

10 (66.7%)

7 (58.3%)

0.964

9 (47.4%)

8 (88.9%)

0.092

1.000

Bilateral breast cancer

13 (23.6%)

4 (26.7%)

2 (16.7%)

0.877

2 (10.5%)

5 (55.6%)

0.035

1.000

Ovarian cancer

4 (7.3%)

2 (13.3%)

1 (8.3%)

1.000

1 (5.3%)

0 (0.0%)

1.000

0.577

Menopausal state

   

0.044

  

0.534

0.404

 Pre- or perimenopausal

39 (70.9%)

9 (60.0%)

12 (100.0%)

13 (68.4%)

5 (55.6%)

  

 Postmenopausal

15 (27.3%)

6 (40.0%)

0 (0.0%)

 

5 (26.3%)

4 (44.4%)

  

 Male

1 (1.8%)

   

1 (5.3%)

0 (0.0%)

  

Prophylactic BSO

28 (50.9%)

8 (53.3%)

6 (50.0%)

1.000

11 (57.9%)

3 (33.3%)

0.418

1.000

Prophylactic mastectomy

8 (14.5%)

4 (26.7%)

2 (16.7%)

0.877

1 (5.3%)

1 (11.1%)

1.000

0.229

TNM stage at diagnosis

  

0.921

  

0.080

0.192

 I

6 (10.9%)

1 (6.7%)

1 (8.3%)

 

1 (5.3%)

3 (33.3%)

  

 II

28 (50.9%)

7 (46.7%)

4 (33.3%)

 

11 (57.9%)

6 (66.7%)

  

 III

16 (29.1%)

5 (33.3%)

5 (41.7%)

 

6 (31.6%)

0 (0.0%)

  

 IV

5 (9.1%)

2 (13.3%)

2 (16.7%)

 

1 (5.3%)

0 (0.0%)

  

Node positive

37 (67.3%)

10 (66.7%)

9 (75.0%)

0.962

16 (84.2%)

2 (22.2%)

0.006

0.847

Subtypes

   

0.218

  

0.185

0.006

Hormone receptor + HER2-

28 (50.9%)

7 (46.6%)

2 (16.7%)

 

11 (78.9%)

4 (44.4%)

  

Hormone receptor + HER2 + 

2 (3.6%)

0 ( 0.0%)

0 ( 0.0%)

 

1 ( 5.3%)

1 (11.1%)

  

TNBC

25 (45.5%)

8 (53.3%)

10 (83.3%)

 

3 (15.8%)

4 (44.4%)

  

Ki-67

10.0 (1–90)

10.0 (1–70)

40.0 (10–90)

0.006

5.0 (1–30)

10.0 (2–20)

0.120

0.036

Relapse

23 (41.8%)

6 (40.0%)

3 (25.0%)

0.681

8 (42.1%)

6 (66.7%)

0.418

0.327

 Local

3 (5.5%)

1 (6.7%)

0 (0.0%)

 

2 (10.5%)

0 (0.0%)

  

 Contralateral

11 (20.0%)

2 (13.3%)

2 (16.7%)

 

2 (10.5%)

5 (55.6%)

  

 Distant metastasis

16 (29.1%)

3 (25.0%)

5 (33.3%)

 

1 (11.1%)

7 (36.8%)

  

Death

7 (12.7%)

1 (6.7%)

1 (8.3%)

1.000

5 (26.3%)

0 (0.0%)

0.242

0.449

  1. gBRCA1 germline BRCA1, gBRCA2 germline BRCA2, BSO bilateral salpingo-oophorectomy
Back to article page

Human Genomics

ISSN: 1479-7364